Clinical significance of TROP2 expression in colorectal cancer

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 3057-3063

  Ohmachi, Takahiro ^a,b,c   Tanaka, Fumiaki ^a,c   Mimori, Koshi ^a,c   Inoue, Hiroshi ^a,c   Yanaga, Katsuhiko ^b   Mori, Masaki ^a,c  

^a KYUSHU UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PROTEIN TROP 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE;

AGED; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 33744800782     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1961     Document Type: Article

References (42)

1. Tsukuma H, Ajiki W, Oshima A. Cancer incidence in Japan. Gan To Kagaku Ryoho 2004;31:840-6.
2. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-65.
3. McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005;48: 1632-50.
4. Wu DH, Liu L, Chen LH. Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells. World J Gastroenterol 2005;11:3051-5.
5. Aggarwal S, Chu E. Current therapies for advanced colorectal cancer. Oncology 2005;19:589-95.
6. Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004;5:115-20.
7. Fornaro M, Dell'Arciprete R, Stella M, et al. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 1995; 62:610-8.
8. Tsujikawa M, Kurahashi H, Tanaka T, et al. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat Genet 1999;21:420-3.
9. Alberti S, Miotti S, Stella M, et al. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma 1992;11:539-45.
10. Miotti S, Canevari S, Menard S, et al. I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987;39:297-303.
11. Fradet Y, Cordon-Cardo C, Thomson T, et al. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 1984;81:224-8.
12. Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA 1981;78:5147-50.
13. Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001;7:2277-84.
14. Nishida K, Mine S, Utsunomiya T, et al. Global analysis of altered gene expressions during the process of esophageal squamous cell carcinogenesis in the rat: a study combined with a laser microdissection and a cDNA microarray. Cancer Res 2005;65:401-9.
15. Pabon C, Modrusan Z, Ruvolo MV, et al. Optimized T7 amplification system for microarray analysis. Biotechniques 2001;31:874-9.
16. Mori M, Mimori K, Yoshikawa Y, et al. Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 2002; 131:339-47.
17. Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11:2889-93.
18. Min Y, Adachi Y, Yamamoto H, et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005;54:591-600.
19. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993;54: 614-8.
20. Skoglund J, Emterling A, Arbman G, Anglard P, Sun XF. Clinicopathological significance of stromelysin-3 expression in colorectal cancer. Oncology 2004;67: 67-72.
21. Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Hofler H. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations. Diagn Mol Pathol 1996;5:284-90.
22. Furuta K, Zahurak M, Goodman SN, Hamilton SR, August JT. CD44 expression in the stromal matrix of colorectal cancer: association with prognosis. Clin Cancer Res 1998;4:21-9.
23. Wielenga VJ, Heider KH, Offerhaus GJ, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-6.
24. Heider KH, Hofmann M, Hors E, et al. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993;120:227-33.
25. Etoh T, Ueo H, Inoue H, et al. Clinical significance of K-Ras mutations in intraoperative tumor drainage blood from patients with colorectal carcinoma. Ann Surg Oncol 2001;8:407-12.
26. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin α(v)β(3) expression in colon carcinoma correlates with survival. Mod Pathol 2001;14: 1126-32.
27. Saeki T, Stromberg K, Qi CF, et al. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res 1992;52:3467-73.
28. Ciardiello F, Kim N, Saeki T, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA 1991; 88:7792-6.
29. Fujita M, Furukawa Y, Tsunoda T, Tanaka T, Ogawa M, Nakamura Y. Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the β-catenin/T-cell factor complex, in colorectal carcinomas. Cancer Res 2001;61:7722-6.
30. Tamai S, Masuda H, Ishii Y, Suzuki S, Kanai Y, Endou H. Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size. Cancer Detect Prev 2001;25:439-45.
31. McIver CM, Lloyd JM, Hewett PJ, Hardingham JE. Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett 2004; 209:67-74.
32. Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut 2001;49:409-17.
33. Zhou S, Buckhaults P, Zawel L, et al. Targeted deletion of Smad4 shows it is required for transforming growth factor β and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A 1998;95:2412-6.
34. Nakashima K, Shimada H, Ochiai T, et al. Serological identification of TROP2 by recombinant c DNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 2004;112: 1029-35.
35. Kanai Y, Ushijima S, Saito Y, Nakanishi Y, Sakamoto M, Hirohashi S. MRNA expression of genes altered by 5-azacytidine treatment in cancer cell lines is associated with clinicopathological parameters of human cancers. J Cancer Res Clin Oncol 2001;127:697-706.
36. Basu A, Goldenberg DM, Stein R. The epithelial/ carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer 1995;62:472-9.
37. McLaughlin S, Murray D. Plasma membrane phosphoinositide organization by protein electrostatics. Nature 2005;438:605-11.
38. 2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer 1998;75:324-30.
39. Mangino G, Grazia Capri M, Barnaba V, Alberti S. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Int J Cancer 2002;101:353-9.
40. Tanaka S, Harada M, Mine T, et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 2003;26:357-66.
41. Tanaka F, Fujie T, Tahara K, et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997;57:4465-8.
42. Tanaka F, Fujie T, Go H, et al. Efficient induction of antitumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol Immunother 1997;44:21-6.